research explores non-invasive inhalable formulations, including dry-powder mRNA vaccines and exosome therapies aimed at organ tissue repair. Xsome Biotech pursues a clinical and preclinical pipeline targeting inflammatory, cancerous, and age-related conditions, with emphasis on acute and chronic lung disorders. Its lead candidate, XO101, is an LSC-Exo-based therapeutic under development for Acute Respiratory Distress Syndrome. The company also advances platform technologies intended to improve mucosal penetration and drug delivery compared with synthetic nanoparticle systems.